Comparison of Dopamine and Norepinephrine in the Treatment of Shock
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0.19 microg per kilogram per minute for norepinephrine, open-label norepinephrine, epinephrine, or vasopressin could be added. The primary outcome was the rate of death at 28 days after randomization; secondary end points included the number of days without need for organ support and the occurrence of adverse events. RESULTS: The trial included 1679 patients, of whom 858 were assigned to dopamine and 821 to norepinephrine. The baseline characteristics of the groups were similar. There was no significant between-group difference in the rate of death at 28 days (52.5% in the dopamine group and 48.5% in the norepinephrine group; odds ratio with dopamine, 1.17; 95% confidence interval, 0.97 to 1.42; P=0.10). However, there were more arrhythmic events among the patients treated with dopamine than among those treated with norepinephrine (207 events [24.1%] vs. 102 events [12.4%], P<0.001). A subgroup analysis showed that dopamine, as compared with norepinephrine, was associated with an increased rate of death at 28 days among the 280 patients with cardiogenic shock but not among the 1044 patients with septic shock or the 263 with hypovolemic shock (P=0.03 for cardiogenic shock, P=0.19 for septic shock, and P=0.84 for hypovolemic shock, in Kaplan-Meier analyses). CONCLUSIONS: Although there was no significant difference in the rate of death between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine, the use of dopamine was associated with a greater number of adverse events. (ClinicalTrials.gov number, NCT00314704.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dopamine (DA) is a neurotransmitter in the catechol family, which is often used as first-line vasoactive drug in patients with septic shock (43).”
From Dopamine Is a Siderophore-Like Iron Chelator That Promotes Salmonella enterica Serovar Typhimurium Virulence in Mice (2019) · cites this paper as [43]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Self-citationWriting Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationCDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Current Epidemiology of Septic Shock: The CUB-Réa Network
Annane, D., Aegerter, P., Jars-Guincestre, M. C., & Guidet, B. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2201087 · Cited by 637
Research works printed but not linked: 1
- Mullner M, 2004, Cochrane Database Syst Rev, 3, CD003709
Cited by
Items 201–300 of 1,000
Sepsis and pregnancy: do we know how to treat this situation?
Cordioli, R. L., Cordioli, E., Negrini, R., & Silva, E. (2013) · Revista Brasileira de Terapia Intensiva · doi:10.5935/0103-507x.20130056 · Cited by 118
Ni, Y.-N., Wang, Y., Liang, B., & Liang, Z.-A. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0810-1 · Cited by 118
Fordyce, C. B., Katz, J. N., Alviar, C. L., Arslanian-Engoren, C., Bohula, E. A., Geller, B. J., Hollenberg, S. M., Jentzer, J. C., Sims, D. B., Washam, J. B., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000909 · Cited by 116
State of Shock: Contemporary Vasopressor and Inotrope Use in Cardiogenic Shock
Bloom, J. E., Chan, W., Kaye, D. M., & Stub, D. A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029787 · Cited by 114
Landoni, G., Augoustides, J. G., Guarracino, F., SANTINI, F., Ponschab, M., Pasero, D., Rodseth, R. N., Biondi‐Zoccai, G., Silvay, G., Salvi, L., et al. (2011) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2010.02381.x · Cited by 113
“Three-hundred-forty participants from 65 countries (Figure 1 and Figure 2) suggested 120 topics: 17 of them were supported by an article with a significant effect on mortality (2-20) while 103 topics were not (Figure 3).”
Update on pediatric sepsis: a review
Kawasaki, T. (2017) · Journal of Intensive Care · doi:10.1186/s40560-017-0240-1 · Cited by 114
“line for adults mainly because of fewer arrhythmic events [3, 73, 74].”
BackgroundManagement of cardiogenic shock complicating acute myocardial infarction: A review
Shah, A. H., Puri, R., & Kalra, A. (2019) · Clinical Cardiology · doi:10.1002/clc.23168 · Cited by 113
“Pre-specified subgroup analysis revealed norepinephrine to be particularly beneficial in patients in cardiogenic shock.(37) Therefore, the European Society of Cardiology (ESC) guidelines for management of STEMI complicated by CS recommend that norepinephrine should be preferred over dopamine when blood pressure is low…”
BackgroundHoller, J. G., Bech, C. N., Henriksen, D. P., Mikkelsen, S., Pedersen, C., & Lassen, A. T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119331 · Cited by 99
Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients
Wolfe, K. S., Patel, B. K., MacKenzie, E. L., Giovanni, S. P., Pohlman, A. S., Churpek, M. M., Hall, J. B., & Kress, J. P. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.07.016 · Cited by 110
Vasopressor Therapy in the Intensive Care Unit
Russell, J. A., Gordon, A. C., Williams, M. D., Boyd, J. H., Walley, K. R., & Kissoon, N. “. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1710320 · Cited by 110
Acute kidney injury in severe sepsis: Pathophysiology, diagnosis, and treatment recommendations
Keir, I., & Kellum, J. A. (2015) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12297 · Cited by 110
Stefanini, G. G., Chiarito, M., Ferrante, G., Cannata, F., Azzolini, E., Viggiani, G., Marco, A. D., Briani, M., Bocciolone, M., Bragato, R., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-317322 · Cited by 109
Acute kidney injury in elderly intensive care patients: a review
Chronopoulos, A., Rosner, M. H., Cruz, D. N., & Ronco, C. (2010) · Intensive Care Medicine · doi:10.1007/s00134-010-1957-7 · Cited by 110
“Conversely, Random controlled trials comparing vasopressors in septic shock treatment were all unable to demonstrate any notable difference in mortality [69–73].”
BackgroundJentzer, J. C., Wiley, B. M., Bennett, C. E., Murphree, D. H., Keegan, M. T., KASHANI, K. B., Bell, M. R., & Barsness, G. W. (2019) · Shock · doi:10.1097/shk.0000000000001390 · Cited by 107
“Therefore, the lower observed mortality with NE in our study may reflect relatively higher mortality in patients receiving EPI or DOPA, which have a propensity to cause harmful excessive beta-adrenergic stimulation and arrhythmias; notably, we did not observe a direct association between use of either DOPA or EPI and…”
BackgroundResultInfluentialSevere Sepsis and Septic Shock: Clinical Overview and Update on Management
Cawcutt, K. A., & Peters, S. G. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.009 · Cited by 106
“Furthermore, low-dose dopamine for renal protection is not recommended.(3,4,22) If a second vasopressor is needed to maintain MAP, epinephrine or vasopressin would be appropriate.”
BackgroundThe science behind percutaneous hemodynamic support: A review and comparison of support strategies
Burkhoff, D., & Naidu, S. S. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24421 · Cited by 105
Mechanical Circulatory Support Devices for Cardiogenic Shock: State of the Art
Hajjar, L. A., & Teboul, J. (2019) · Critical Care · doi:10.1186/s13054-019-2368-y · Cited by 104
Microcirculatory dysfunction and resuscitation: why, when, and how
Moore, J. P. R., Dyson, A., Singer, M., & Fraser, J. F. (2015) · British Journal of Anaesthesia · doi:10.1093/bja/aev163 · Cited by 102
Datt, V., Wadhhwa, R., Sharma, V., Virmani, S., Minhas, H. S., & Malik, S. (2021) · Journal of Cardiac Surgery · doi:10.1111/jocs.15805 · Cited by 102
Echocardiography as a guide for fluid management
Boyd, J. H., Sirounis, D., Maizel, J., & Slama, M. (2016) · Critical Care · doi:10.1186/s13054-016-1407-1 · Cited by 102
Vasopressors for hypotensive shock
Havel, C., Arrich, J., Losert, H., Gamper, G., Müllner, M., & Herkner, H. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003709.pub3 · Cited by 77
Challenges in the management of septic shock: a narrative review
Backer, D. D., Cecconi, M., Lipman, J., Machado, F. R., Myatra, S. N., Ostermann, M., Perner, A., Teboul, J., Vincent, J., & Walley, K. R. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05544-x · Cited by 102
Self-citationJoint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices
Chieffo, A., Dudek, D., Hassager, C., Combes, A., Gramegna, M., Halvorsen, S., Huber, K., Kunadian, V., Malý, J., Møller, J. E., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab015 · Cited by 101
Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury
Wong, B. T., Chan, M. J., Glassford, N. J., Mårtensson, J., Bion, V., Chai, S. Y., Oughton, C., Tsuji, I. Y., Lluch-Candal, C., & Bellomo, R. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2015.05.003 · Cited by 101
“Similarly, the time-weighted CVP of 10 mm Hg was also consistent with current recommendations [2] and within the range reported in previous landmark trials [1,27], with an MPP of 63 mm Hg.”
ResultSepsis and Septic Shock Strategies
Armstrong, B., Betzold, R., & May, A. K. (2017) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.07.003 · Cited by 100
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
Predictors of Outcomes in Myocardial Infarction and Cardiogenic Shock
Acharya, D. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000190 · Cited by 99
Expert statement for the management of hypovolemia in sepsis
Perner, A., Cecconi, M., Cronhjort, M., Darmon, M., Jakob, S. M., Pettilä, V., & van der Horst, I. C. C. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5177-x · Cited by 97
Severe community-acquired pneumonia: timely management measures in the first 24 hours
Phua, J., Dean, N. C., Guo, Q., Kuan, W. S., Lim, H. F., & Lim, T. K. (2016) · Critical Care · doi:10.1186/s13054-016-1414-2 · Cited by 96
“rine may be infused for septic shock [103] and lung-”
BackgroundLakhal, K., Hivert, A., Alexandre, P.-L., Fresco, M., Robert-Edan, V., Rodie-Talbere, P.-A., Ambrosi, X., Bourcier, R., Rozec, B. R., & Cadiet, J. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01331-z · Cited by 96
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 96
The Japanese guidelines for the management of sepsis
Oda, S., Aibiki, M., Ikeda, T., Imaizumi, H., Endo, S., Ochiai, R., Kotani, J., Shime, N., Nishida, O., Noguchi, T., et al. (2014) · Journal of Intensive Care · doi:10.1186/s40560-014-0055-2 · Cited by 95
Sitkowska, K., Hoes, M. F., Lerch, M. M., Lameijer, L. N., van der Meer, P., Szymański, W., & Feringa, B. L. (2020) · Chemical Communications · doi:10.1039/d0cc02178d · Cited by 95
Vasopressor Therapy in Cardiac Surgery—An Experts’ Consensus Statement
Guarracino, F., Habicher, M., Treskatsch, S., Sander, M., Székely, A. D., Paternoster, G., Salvi, L., Łysenko, L., Gaudard, P., Giannakopoulos, P., et al. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.11.032 · Cited by 97
Görenek, B., Lundqvist, C. B., Brugada, J., Camm, A. J., Hindricks, G., Huber, K., Kirchhof, P. F., Kück, K., Kudaiberdieva, G., Lin, T., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m08_19 · Cited by 95
Complications and outcomes of vasopressor usage in acute traumatic central cord syndrome
Readdy, W. J., Whetstone, W. D., Ferguson, A. R., Talbott, J. F., Inoue, T., Saigal, R., Bresnahan, J. C., Beattie, M. S., Pan, J. Z., Manley, G. T., et al. (2015) · Journal of Neurosurgery Spine · doi:10.3171/2015.2.spine14746 · Cited by 95
Na, S. J., Chung, C. R., Cho, Y. H., Jeon, K., Suh, G. Y., Ahn, J., Carriere, K. C., Park, T. K., Lee, G. Y., Lee, J. M., et al. (2018) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.12.020 · Cited by 92
Severe sepsis and septic shock: Management and performance improvement
Schorr, C., Zanotti, S. L., & Dellinger, R. P. (2013) · Virulence · doi:10.4161/viru.27409 · Cited by 92
Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Mario, C. D., Dickstein, K., Ducrocq, G., Fernández‐Avilés, F., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.10.014 · Cited by 91
A team‐based approach to patients in cardiogenic shock
Doll, J. A., Ohman, E. M., Patel, M. R., Milano, C. A., Rogers, J. G., Wohns, D., Kapur, N. K., & Rao, S. V. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26297 · Cited by 91
“However, arrhythmias were more common in the dopamine group, and subgroup analysis showed increased mortality among the patients with cardiogenic shock when dopamine was used [14].”
BackgroundPerman, S. M., Goyal, M. K., & Gaieski, D. F. (2012) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/1757-7241-20-41 · Cited by 91
“[44] If patients were not responsive to titrated dosing of either medication, open label use of a second vasopressor was allowed.”
BackgroundNa, S. J., Chung, C. R., Cho, Y. H., Jeon, K., Suh, G. Y., Ahn, J., Carriere, K. C., Park, T. K., Lee, G. Y., Lee, J. M., et al. (2018) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.01.003 · Cited by 90
“Hospital 14 [8-39] 16 [9-46] 18 [8-47] 20 [11-54] 17 [4-37] .”
Bistola, V., Arfaras-Melainis, A., Polyzogopoulou, E., Ikonomidis, I., & Parissis, J. (2019) · Cardiac failure review · doi:10.15420/cfr.2019.11.2 · Cited by 90
“Notably, a subgroup analysis from the same trial including only patients with cardiogenic shock showed that norepinephrine was superior to dopamine in terms of reduction in mortality.(16)”
ResultThe trefoil protein TFF1 is bound to MUC5AC in humangastric mucosa
Ruchaud‐Sparagano, M., Westley, B. R., & May, F. E. B. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4124-x · Cited by 90
The hemodynamic effects of norepinephrine: far more than an increase in blood pressure!
Foulon, P., & Backer, D. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.09.27 · Cited by 90
“Compared to dopamine, norepinephrine improves outcome in patients with septic shock (1) and in cardiogenic shock (2).”
BackgroundBelletti, A., Benedetto, U., Biondi-Zoccai, G., Leggieri, C., Silvani, P., Angelini, G. D., Zangrillo, A., & Landoni, G. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2016.08.010 · Cited by 88
“Literature search was last updated June 30th, 2015 and the full PubMed search strategy, modified from Biondi-Zoccai et al [21], is available in the Supplementary Material.”
BackgroundInfluentialBurstein, B. J., Tabi, M., Barsness, G. W., Bell, M. R., KASHANI, K. B., & Jentzer, J. C. (2020) · Critical Care · doi:10.1186/s13054-020-03217-6 · Cited by 88
“Evidence supports the use of vasopressors such as norepinephrine that have a lower rate of cardiovascular adverse events, including increased myocardial oxygen demand, ischemia, arrhythmias, and mortality [1, 14].”
BackgroundWong, A. S. K., & Sin, W. C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2171 · Cited by 87
“Vasopressors and inotropes augment cardiac output and organ perfusion but at the expense of increasing myocardial oxygen consumption, compromising tissue microcirculation, and inducing arrhythmias (1,2).”
BackgroundManagement of Acute Coronary Syndrome
Atwood, J. (2022) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2022.06.008 · Cited by 87
Kleinman, M. E., de Caen, A. R., Chameides, L., Atkins, D. L., Berg, R. A., Berg, M. D., Bhanji, F., Biarent, D., Bingham, R., Coovadia, A. H., et al. (2010) · Pediatrics · doi:10.1542/peds.2010-2972a · Cited by 86
Ltaief, Z., Ben‐Hamouda, N., Rancati, V., Gunga, Z., Marcucci, C., Kirsch, M. E. W., & Liaudet, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216407 · Cited by 86
“6% of all forms of circulatory shock [9].”
BackgroundStaphylococcal Toxic Shock Syndrome: Mechanisms and Management
Silversides, J. A., Lappin, E., & Ferguson, A. J. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0119-y · Cited by 86
“Many units prefer norepinephrine because of its side-effect profile [41].”
BackgroundSmith, S. H., & Perner, A. (2012) · Critical Care · doi:10.1186/cc11333 · Cited by 77
“01 μg/kg per minute norepinephrine [11].”
Septic Shock — Evaluating Another Failed Treatment
Wenzel, R. P., & Edmond, M. B. (2012) · New England Journal of Medicine · doi:10.1056/nejme1203412 · Cited by 85
van Paridon, B. M., Sheppard, C., Garcia Guerra, G., Joffe, A. R., & for the Alberta Sepsis Network (2015) · Critical Care · doi:10.1186/s13054-015-1010-x · Cited by 84
“Third, because of the small cohort, we did not analyze outcomes according to individual agents; it is possible that one agent may be better than another in determining outcome, although this has not been shown in adult studies [41, 42].”
BackgroundLactic acidosis: Clinical implications and management strategies
Reddy, A. J., Lam, S. W., Bauer, S. R., & Guzmán, J. A. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14098 · Cited by 84
Catapano, J. S., Hawryluk, G. W. J., Whetstone, W. D., Saigal, R., Ferguson, A. R., Talbott, J. F., Bresnahan, J. C., Dhall, S. S., Pan, J. Z., Beattie, M. S., et al. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.08.053 · Cited by 84
Vignon, P., Bégot, E., Mari, A., Silva, S., Chimot, L., Delour, P., Vargas, F., Filloux, B., Vandroux, D., Jabot, J., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.08.022 · Cited by 83
Corrêa, T. D., Vuda, M., Takala, J. A., Djafarzadeh, S., Silva, E., & Jakob, S. M. (2013) · Critical Care · doi:10.1186/cc12495 · Cited by 83
“Data from experimental [24,28] and clinical studies [15,29-37] have shown that therapeutic attempts, including administration of fluids and vasopressors to restore hemodynamic stability during sepsis may be associated with poor outcomes.”
BackgroundVasopressor and Inotrope Therapy in Cardiac Critical Care
Jentzer, J. C., & Hollenberg, S. M. (2020) · Journal of Intensive Care Medicine · doi:10.1177/0885066620917630 · Cited by 81
“Many patients with severe shock fail to meet MAP goals with DOPA alone, likely because its indirect mechanism of action relies on release of NE from adrenergic nerve terminals, which can be exhausted.(47,53,62) For these reasons, we do not think DOPA has a role as a vasopressor for any common patient population, and w…”
BackgroundInfluentialCurrent use of inotropes in circulatory shock
Scheeren, T., Bakker, J., Kaufmann, T., Annane, D., Asfar, P., Boerma, E. C., Cecconi, M., Chew, M. S., Cholley, B., Cronhjort, M., et al. (2021) · Annals of Intensive Care · doi:10.1186/s13613-021-00806-8 · Cited by 82
“Critically ill patients present with one or a combination of these four types of circulatory failure [4].”
BackgroundSelf-citationMinimizing catecholamines and optimizing perfusion
Backer, D. D., & Foulon, P. (2019) · Critical Care · doi:10.1186/s13054-019-2433-6 · Cited by 81
Protein C and acute inflammation: a clinical and biological perspective
Christiaans, S. C., Wagener, B. M., Esmon, C. T., & Pittet, J. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00093.2013 · Cited by 80
“(35–50%) (23, 70) and raised the question of whether this trial”
BackgroundSurviving sepsis: going beyond the guidelines
Marik, P. E. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-17 · Cited by 80
“In a large randomized, controlled trial, De Backer and colleagues compared dopamine with norepinephrine for the treatment of patients with shock [35].”
BackgroundEvolving Concepts in Diagnosis and Management of Cardiogenic Shock
Bellumkonda, L., Gül, B., & Masri, S. C. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.05.040 · Cited by 79
Timing of vasoactive agents and corticosteroid initiation in septic shock
Ammar, M. A., Ammar, A. A., Wieruszewski, P. M., Bissell, B. D., Long, M. T., Albert, L., Khanna, A. K., & Sacha, G. L. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-01021-9 · Cited by 78
Prognostic impact of restored sinus rhythm in patients with sepsis and new-onset atrial fibrillation
Liu, W. C., Lin, W. Y., Lin, C. S., Huang, H., Lin, T. C., Cheng, S. M., Yang, S. P., Lin, J. C., & Lin, W. S. (2016) · Critical Care · doi:10.1186/s13054-016-1548-2 · Cited by 78
“Vasopressor agents, particularly those with β-adrenergic effects, may also play a direct role in triggering NeOAF [14, 18, 24, 33].”
BackgroundInotropes and vasopressors use in cardiogenic shock: when, which and how much?
Lévy, B., Buzon, J., & Kimmoun, A. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000632 · Cited by 78
Averkov, O. V., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Nikulina, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Abugov, S. A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6319 · Cited by 77
Maharaj, R., & Metaxa, V. (2011) · Critical Care · doi:10.1186/cc10263 · Cited by 78
“Data on comparison between inotropes are scant and recent reports have highlighted the challenge in selecting the best pharmacologic option [17-19].”
BackgroundHammond, D. A., Ficek, O. A., Painter, J. T., McCain, K., Cullen, J., Brotherton, A. L., Kakkera, K. S. S., Chopra, D., & Meena, N. K. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2105 · Cited by 77
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs
Schally, A. V., Szepesházi, K., Nagy, A., Schally, A. V., & Halmos, G. B. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3434-3 · Cited by 77
Management of nephrotoxicity of chemotherapy and targeted agents: 2020.
Chiruvella, V., Annamaraju, P., & Guddati, A. K. (2020) · American Journal of Cancer Research · Cited by 76
Multimodal strategy to counteract vasodilation in septic shock
Léone, M., Einav, S., Antonucci, E., Dépret, F., Lakbar, I., Martín‐Loeches, I., Wieruszewski, P. M., Myatra, S. N., & Khanna, A. K. (2023) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2023.101193 · Cited by 76
Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Kimmoun, A., Ducrocq, N., & Lévy, B. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111311020004 · Cited by 76
“However, dopamine compared to norepinephrine is associated with much more arrhythmia and should be abandoned [66].”
BackgroundAcute Right Ventricular Dysfunction in Intensive Care Unit
Grignola, J. C., & Domingo, E. (2017) · BioMed Research International · doi:10.1155/2017/8217105 · Cited by 76
“At moderate-high doses of dopamine, PVR/SVR ratio increases [86] (Table 3).”
BackgroundImproving Survival From Cardiac Arrest: A Review of Contemporary Practice and Challenges
Jentzer, J. C., Clements, C. M., Wright, R. S., White, R. D., & Jaffe, A. S. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.05.022 · Cited by 75
Dakson, A., Brandman, D. M., Thibault-Halman, G., & Christie, S. (2017) · Spinal Cord · doi:10.1038/sc.2017.52 · Cited by 75
Gustafsson, F., Damman, K., Nalbantgil, S., Laake, L. W. V., Tops, L. F., Thum, T., Adamopoulos, S. N., Bonios, M. J., Coats, A. J. S., Crespo-Leiro, M. G., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2814 · Cited by 75
Du, W., Liu, D., Wang, X., Long, Y., Chai, W., Zhou, X. Q., & Xi, R. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2013.07.049 · Cited by 74
“Interestingly, the use of dopamine has previously been associated with a greater number of adverse events [13].”
BackgroundFarmakis, D. T., Agostoni, P., Baholli, L., Баутин, А. Е., Colet, J. C., Crespo-Leiro, M. G., Fedele, F., García‐Pinilla, J. M., Giannakoulas, G. A., Grigioni, F., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.09.005 · Cited by 74
Pediatric acute kidney injury: A syndrome under paradigm shift
Ashraf, M., Shahzad, N., Irshad, M., Hussain, S. Q., & Ahmed, P. (2014) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.138156 · Cited by 73
“[80] In fact, dopamine may be associated with increased arrhythmic complications.[81] If vasopressor support is required, norepinephrine should be preferred.”
BackgroundMethylene blue administration in patients with refractory distributive shock – a retrospective study
Pořízka, M., Kopecký, P., Dvorakova, H., Kunstýř, J., Lipš, M., Michálek, P., & Balík, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-58828-4 · Cited by 73
Roy, T. K., & Secomb, T. W. (2020) · Microcirculation · doi:10.1111/micc.12673 · Cited by 73
Mauricio, E. C. B., Lopes, M. C. B. T., Batista, R. E. A., Okuno, M. F. P., & Campanharo, C. R. V. (2018) · Revista Latino-Americana de Enfermagem · doi:10.1590/1518-8345.2308.2993 · Cited by 73
Basir, M. B., Lemor, A., Gorgis, S., Taylor, A. M., Tehrani, B. N., Truesdell, A. G., Bharadwaj, A. S., Kolski, B. C., Patel, K., Gelormini, J. L., et al. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29895 · Cited by 73
“In the largest randomized controlled trial evaluating outcomes of vasopressors in shock, dopamine was found to be associated with increased mortality when compared to norepinephrine in the prespecified cardiogenic shock subgroup.(4) Dopamine was associated with increased heart rate and more arrhythmic events.”
Tagami, T., Matsui, H., Horiguchi, H., Fushimi, K., & Yasunaga, H. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12786 · Cited by 72
Noradrenaline use for septic shock in children: doses, routes of administration and complications
Lampin, M., Rousseaux, J., Botte, A., Sadik, A., Cremer, R., & Leclerc, F. (2012) · Acta Paediatrica · doi:10.1111/j.1651-2227.2012.02725.x · Cited by 72
“6 lg ⁄ kg per min (12) in order to avoid arrhythmias, higher doses of”
BackgroundAmbrus, D. B., Benjamin, E. J., Bajwa, E. K., Hibbert, K. A., & Walkey, A. J. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2015.06.003 · Cited by 72
“Prior studies using population-based [2,3], singlecenter [7-9], or trial [10] data have shown that acute factors (eg, choice of vasopressor, acute organ failures, mechanical ventilation, and right heart catheterization), rather than preexisting cardiovascular comorbidities [11,12] are associated with increased risk fo…”
Jena, A. B., Prasad, V. K., Goldman, D. P., & Romley, J. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.6781 · Cited by 72
Sepsis With Preexisting Heart Failure: Management of Confounding Clinical Features
Jones, T. W., Smith, S. E., Tuyl, J. S. V., & Sikora, A. N. (2020) · Journal of Intensive Care Medicine · doi:10.1177/0885066620928299 · Cited by 73
“03) and lower incidence of arrhythmias within all variations of shock (ie, hypovolemic, septic, and cardiogenic).(103) In keeping with these results, a 2015 meta-analysis prompted guidelines to recommend NE over dopamine as first line in septic shock as it demonstrated lower mortality (risk ratio [RR]: 0.”
BackgroundMethodResultInfluentialGuinot, P., Longrois, D., Kamel, S., Lorne, E., & Dupont, H. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002772 · Cited by 71
Itenov, T. S., Johansen, M. E., Bestle, M. H., Þormar, K., Hein, L., Gyldensted, L., Lindhardt, A., Christensen, H. K., Estrup, S., Pedersen, H. P., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30004-3 · Cited by 71
Moreno, R. P., Rhodes, A., Ranzani, O., Salluh, J. I., Berger‐Estilita, J., Coopersmith, C. M., Juffermans, N. P., Laffey, J. G., Reinikainen, M., Neto, A. S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.45040 · Cited by 70
Self-citationThiele, H., & Hassager, C. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2312086 · Cited by 70
Perez, P., Kimmoun, A., Blime, V., & Lévy, B. (2014) · Shock · doi:10.1097/shk.0000000000000099 · Cited by 70
“Despite the absence of level A studies, it appears that norepinephrine is the vasopressor of choice in cardiogenic shock (10, 11).”
BackgroundCardiogenic shock: evolving definitions and future directions in management
Jones, T. L., Nakamura, K., & McCabe, J. M. (2019) · Open Heart · doi:10.1136/openhrt-2018-000960 · Cited by 70
“Ionovasodilator and vasopressor therapies have demonstrated limited benefit in CS and are often counterproductive.(41) 42 MCS to improve haemodynamics and perfusion is increasingly available following proliferation of rapidly initiated percutaneous left ventricular assist devices (pLVAD).”
BackgroundCorrêa, T. D., Vuda, M., Blaser, A. R., Takala, J. A., Djafarzadeh, S., Dünser, M. W., Silva, E., Lensch, M., Wilkens, L., & Jakob, S. M. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31825b916b · Cited by 69
Guinot, P., Bernard, E., Levrard, M., Dupont, H., & Lorne, E. (2015) · Critical Care · doi:10.1186/s13054-014-0732-5 · Cited by 69
“Treatment of circulatory shock must include correction of the cause of shock and hemodynamic stabilization, primarily by fluid infusion and administration of vasoactive agents [2,3].”
BackgroundManagement of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?
Kamath, S., Altaq, H. H., & Abdo, T. (2023) · Microorganisms · doi:10.3390/microorganisms11092231 · Cited by 69
“…dopamine and norepinephrine in the treatment of shock showed no difference in 28-day mortality but a significantly higher risk of arrhythmia with dopamine (24.1% vs. 12.4%, p 0.001), making norepinephrine the vasopressor of choice for septic patients in the 2012 SSC guidelines update [35,80].”
Influential
Metadata
- Authors
- De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L.
- Affiliations
- Université Libre de Bruxelles (BE)
- Medical University of Vienna (AT)
- Centre hospitalier Etterbeek-Ixelles (BE)
- Erasmus Hospital (BE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-04
- Volume
- 362
- Issue
- 9
- Pages
- 779-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095944485
- Cited by
- 1,940
- References
- 31
- Citations by year
- 2026: 98 · 2025: 107 · 2024: 140 · 2023: 115 · 2022: 125 · 2021: 132 · 2020: 135 · 2019: 138 · 2018: 106 · 2017: 139 · 2016: 99 · 2015: 122 · 2014: 120 · 2013: 96 · 2012: 110
- FWCI
- 83.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
- Keywords
- dopamine, norepinephrine, vasopressors, shock, cardiogenic shock, septic shock, hypovolemic shock, 28-day mortality, cardiac arrhythmias, epinephrine, vasopressin, organ support, adverse events, subgroup analysis, vasopressor weaning
- MeSH terms
- Aged, Arrhythmias, Cardiac, Combined Modality Therapy, Dopamine, Female, Fluid Therapy, Humans, Male, Middle Aged, Norepinephrine, Shock, Vasoconstrictor Agents, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.